Biotech Opportunities And Risks In Q2 – And Beyond
After a challenging first quarter of 2021 for biotech investors, what does the second quarter – and, beyond that, the second half of 2021 –…
After a challenging first quarter of 2021 for biotech investors, what does the second quarter – and, beyond that, the second half of 2021 –…
“With West Texas Intermediate (WTI) crude trading near the $60 a barrel level, and expected to go even higher this summer, these could all have…
“After lagging the broad market rebound in 2020, smaller companies staged a comeback in the latter part of that year and have been on a…
“The biotech industry seems poised to continue its good run on the back of continued advancements in the field of research and subsequent speeding up…
As the economic recovery continues, Goldman Sachs is advising investors to “balance the appeal of promising businesses with the risk that [interest] rates rise further…
This previously little-known immunotherapy stock recently saw its shares soar nearly 249% — and its market value surge from $300 million to more than $1…
In 2021, “The big stories…could come from vaccines that haven’t made it to market yet. It’s possible that the stocks of the companies developing these…
“The dumb money was the smart money this year,” is how one portfolio manager cited in today’s article sums up the wild swings experienced by…
In a new research report, Stifel identifies its 2021 picks from the biotech sector – and today’s article highlights the five Buy-rated stocks from that…
“Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher…